Cellvizio shows DDW momentum

Cellvizio is an endoscopy imaging platform, but the real story here is not just better pictures. It is about whether gastroenterologists can make more decisions during the proce(maunakeatech.com)h centered on pancreatic cysts but also extending into gastric cancer, inflammatory bowel disease, and food intolerance. That is a bigger footprint than the company highlighted for DDW 2025, when it pointed to at least eight presentations. (maunakeatech.com) ### What is Cellvizio actually doi(maunakeatech.com)one, the endoscopist can look at tissue architecture in real time, at near-cellular resolution, while the scope is still in place. That is why the company keeps framing it as “real-time cellular imaging,” not just another visualization add-on. (maunakeatech.com) ### Why are pancreatic cysts the main event? Because pancreatic cyst work is where Cellvizio has the clearest clinical pitch. Pancreatic cysts are common, but the hard part is sortin(maunakeatech.com)tudy yet in pancreatic cysts, and ClinicalTrials.gov shows the trial is specifically designed around using confocal laser endomicroscopy as an imaging biomarker for diagnosing pancreatic cystic lesions. (maunakeatech.com) ### Why does the CLIMB slot matter so much? Because DDW has lots of abstrac(maunakeatech.com) flagged that selection separately in March as a “major milestone,” which tells you the company sees this as external validation from the GI field, not just more conference volume. (maunakeatech.com) ### What changed versus last year? The scope widened. In 2025, Mauna Kea highlighted eight DDW presentations focused on pancreatic cysts and pancreatic cancer, food i(maunakeatech.com) lesions, early gastric cancer detection, AI-assisted IBD assessment, and food intolerance diagnosis. That looks like a shift from proving the tool works in one niche to showing it can support a broader GI platform story. (maunakeatech.com)ng, on the spot, whether to aspirate more fluid, where to target sampling, or whether collected material is likely to be enough for cell-block analysis and downstream characterization. A modality that gives in-procedure microscopic feedback could change those calls in real time. That is an inference from the technology’s intended use and the trial design — but it is the commercial logic underneath all this momentum. (clinicaltrials.gov) ### Why mention IBD and gastric cancer too? Because those indications make th(maunakeatech.com)ng similar on the oncology side — it argues the same core hardware can matter in surveillance and lesion characterization outside the pancreas. (maunakeatech.com) ### Is this commercial momentum or just conference optics? Some of it is optics — conference abstract counts always are. But there is more here. Mauna Kea says DDW 2026 will also include its largest-ever Pancreatic Cyst Consortium Meeting with more than 100 interventional endoscopists, plus a U. (clinicaltrials.gov)company is using DDW as both a scientific and go-to-market event. (maunakeatech.com) ### Bottom line? The interesting part is not that Cellvizio got 10 abstracts. It is that the abstracts cluster around decision points where endoscopists hate uncertainty. If CLIMB and the related DDW data show reproducible, multicenter value, Cellvizio starts to look less like a fancy imaging accessory and more like a tool that can reshape GI procedure workflow. (maunakeatech.com)